Tag Archives: Lycera

January, 2017

  • 4 January

    Lycera’s RORgamma Agonist to Begin Phase 1 Trials

    NEW YORK and ANN ARBOR, Mich., January 4, 2017 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today the initiation of a Phase 1/2a clinical trial of the Company’s novel immuno-oncology therapeutic candidate LYC-55716, in patients with advanced, relapsed, or refractory solid tumors. “We …

June, 2015